Angiotensin-converting enzyme inhibitors in heart failure.
Recognition of the importance of the renin-angiotension-aldosterone system in heart failure, along with an appreciation of the hemodynamic benefits of vasodilator therapy has led to the widespread use of angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure. The ACE inhibitors are the only class of vasodilator agents shown to have a significant protective effect against mortality in patients with heart failure.
Borek
M
M
Department of Medicine, Long Island College Hospital, Brooklyn, New York.
Charlap
S
S
Frishman
W H
WH
D000450:Aldosterone / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004573:Electrolytes / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D012084:Renin-Angiotensin System
D000806:Angiotensin-Converting Enzyme Inhibitors; D004573:Electrolytes; D000450:Aldosterone